亨廷顿病:新兴的治疗领域 (综述)
Aisha Tahir1, Sania Jamal2, Usman Ali Shams3
1Department of Biochemistry, University of Health Sciences, Khayaban-e- Jamia Punjab, 54600, Lahore, Punjab, Pakistan. dr.aisha@uhs.edu.pk.
Neurogenetics
|September 6, 2025
概括
亨廷顿病是一种遗传性神经退行性疾病. 新兴的疗法旨在通过向突变的亨廷丁蛋白来改变这种疾病,
科学领域:
- 神经科学
- 遗传学
- 分子生物学
背景情况:
- 亨廷顿病 (HD) 是一种进展性神经退行性疾病.
- 它的特点是运动,认知和精神症状.
- 疾病源于HTT基因的CAG重复扩张,导致有毒的突变狩猎蛋白聚合.
研究的目的:
- 检查亨廷顿病的发病情况.
- 讨论当前和新兴的HD治疗策略.
- 突出转向疾病修饰干预措施.
主要方法:
- 对HD病变发生的遗传,分子和环境因素的文献审查.
- 分析目前的管理方法.
- 探索新的治疗策略,包括RNA干扰,反意义寡核酸 (ASO),抑制剂和CRISPR/Cas9基因编辑.
主要成果:
- 确定了导致HD的关键遗传,分子和环境因素.
- 详细介绍了各种管理策略.
- 展示了有前途的疾病修饰疗法,
结论:
- 新型治疗方法的进步表明, 疾病的进展正在改变.
- 尽管有进展, 亨廷顿病的确切治疗需要进一步的研究.
- 持续的临床和转化研究对于开发有效治疗非常重要.
相关概念视频
Parkinson's Disease: Treatment
375
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
375
Parkinson's Disease: Overview
702
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
702
Direct-Acting Cholinergic Agonists: Therapeutic Uses
866
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
866
Cholinergic Antagonists: Therapeutic Uses
866
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
866
Drugs Affecting Neurotransmitter Synthesis
1.6K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.6K
Alzheimer's Disease: Treatment
260
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
260


